Identifying why TPD is the best approach for a target is the first step to becoming the standard of care. In this session, you will explore key factors that determine when a degrader is the best strategy for your target and how to differentiate it from traditional inhibitors. We will cover:

• The unique advantages of degraders: When and why TPD outperforms conventional approaches
• The advantages of a TPD approach versus using inhibition only in regulating BRAF-V600 mutant MAPK pathway signaling in cancer
• Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate robust anticancer activity in pre-clinical models